

BIBLIOGRAPHY

Publications in Peer-reviewed Journals

- 42) Harbour S, Every A, Edwards S & **Sutton P.** (2008) Systemic immunization with unadjuvanted whole *Helicobacter pylori* protects mice against heterologous challenge. *Helicobacter* (accepted 19th June 2008) (IF = 2.42)
- 41) Every A, Chionh Y-T, Skene C, McGuckin M & **Sutton P.** (2008) Muc1 limits *Helicobacter felis* binding to gastric epithelial cells but does not limit colonisation and gastric pathology following infection. *Helicobacter* (accepted 7th June 2008). (IF = 2.42)
- 40) Wee J, Scheerlinck J-P, Snibson K, Edwards S, Pearse M, Quinn C & **Sutton P.** (2008) Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. *Mucosal Immunology* 1: 489-496.
- 39) Cripps A, **Sutton P.**, Beagley K, Robertson S & Dunkley M. Meeting Report Special Interest Group in Mucosal Immunology Workshop, Australasian Society for Immunology, Sydney, Australia, 2 December 2007. *Immunology and Cell Biology* 86: 557-561. (IF = 3.03)
- 38) Skene C, Doidge C and **Sutton P.** (2008) Evaluation of ISCOMATRIX™ and ISCOM™ vaccines for immunisation against *Helicobacter pylori*. *Vaccine* 26: 3880-3884. (IF = 3.16)
- 37) Scheerlinck J-P, Snibson K, Bowles V & **Sutton P.** (2008) Biomedical applications of sheep models: From asthma to vaccines. *Trends in Biotechnology* 26: 259-266. (IF=7.843) [Invited review]
- 36) Linden S, **Sutton P.**, Karlsson N, Korolik V, McGuckin M. (2008) Mucins in the mucosal barrier to bacterial infection. *Mucosal Immunology* 1: 183-197. [Review]
- 35) Harbour S & **Sutton P.** (2008) Immunogenicity and pathogenicity of *Helicobacter* infections of veterinary animals. *Veterinary Immunology and Immunopathology* 122: 191-203. [Invited review]
- 34) McGuckin M, Every A, Skene C, Linden S, Chionh Y-T, Swierczak A, McAuley J, Swierczak A, Harbour S, Kaparakis M, Ferrero R & **Sutton P.** (2007) Muc1 mucin limits both *Helicobacter pylori* colonization of the murine gastric mucosa and associated gastritis. *Gastroenterology* 133: 1210-1218. (IF=12.457)
- 33) Skene C, Young A, Every A & **Sutton P.** (2007) *Helicobacter pylori* flagella: Antigenic profile and protective immunity. *FEMS Immunology and Medical Microbiology* 50: 249-256.
- 32) **Sutton P.**, Doidge C, Pinczower G, Wilson J, Harbour S, Swierczak A & Lee A. (2007) Effectiveness of vaccination with recombinant HpaA from *Helicobacter*

pylori is influenced by host genetic background. *FEMS Immunology and Medical Microbiology* **50**: 213-219.

- 31) **Sutton P.** (2007) Considering increased mouse stomach mass, when calculating prophylactic vaccine efficacy against *Helicobacter pylori*. *Helicobacter* **12**: 210-212. (IF = 2.42)
- 30) Skene C & **Sutton P.** (2006) Saponin-adjuvanted particulate vaccines for clinical use. *Methods* **40**: 53-58. [Invited Review] (IF = 3.82)
- 29) Scheerlinck J-P, Gekas S, Yen H-H, Edwards S, Pearse M, Coulter A & **Sutton P.** (2006) Local immune responses following nasal delivery of an adjuvanted influenza vaccine. *Vaccine* **24**: 3929-3936.
- 28) Yen H-H, Scheerlinck J-P, Gekas S & **Sutton P.** (2006) A sheep cannulation model for evaluation of nasal vaccine delivery. *Methods* **38**: 117-123. (IF = 3.82)
- 27) **Sutton P.**, O'Rourke J, Wilson J, Dixon MF & Lee A. (2004) Immunisation against *Helicobacter felis* infection protects against the development of gastric MALT lymphoma. *Vaccine* **22**: 2541-2546.
- 26) Mueller A, O'Rourke J, Chu P, Kim C, **Sutton P.**, Lee A & Falkow S. (2003) Protective immunity against *Helicobacter* is characterized by a unique transcriptional signal. *Proc Nat Acad Sci* **100**: 12289-12294. (IF=9.643)
- 25) **Sutton P** & Doidge C. (2003) *Helicobacter pylori* vaccines spiral into the new millennium. *Digestive and Liver Disease* **35**: 675-687. [Invited review]
- 24) Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, **Sutton P.**, Rockman S & Pearse M. (2003) Intranasal vaccination with ISCOMATRIX[®] adjuvanted influenza vaccine. *Vaccine* **21**: 946-949.
- 23) **Sutton P.**, Danon S, Walker M, Thompson L, Wilson J, Kosaka T & Lee A. (2001) Post-immunisation gastritis and *Helicobacter* infection in the mouse: A long term study. *Gut* **49**: 467-473.
- 22) Morgner A, **Sutton P.**, O'Rourke J, Enno A, Dixon M & Lee A. (2001) *Helicobacter*-induced expression of Bcl-xL in B lymphocytes in the mouse model: A possible step in the development of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. *International Journal of Cancer* **92**: 634-640.
- 21) **Sutton P.** (2001) Progress in vaccination against *Helicobacter pylori*. *Vaccine* **19**: 2286-2290. [Invited review]
- 20) **Sutton P.** (2001) *Helicobacter pylori* vaccines and mechanisms of effective immunity: Is mucus the key? *Immunology and Cell Biology* **79**: 67-73. [Invited theoretical article] (IF = 3.03).
- 19) **Sutton P** & Lee A. (2000) *Helicobacter pylori* vaccines: The current status. *Alimentary Pharmacology and Therapeutics* **14**: 1107-1118. [Invited review]

- 18) **Sutton P**, Kolesnikow T, Danon S, Wilson J & Lee A. (2000) Dominant non-responsiveness to *Helicobacter pylori* infection is associated with production of Interleukin 10 but not Interferon γ . *Infection and Immunity* **68**: 4802-4804.
- 17) **Sutton P**, Wilson J & Lee A. (2000) Further development of the *Helicobacter pylori* mouse vaccination model. *Vaccine* **18**: 2677-2685.
- 16) **Sutton P**, Wilson J, Kosaka T, Wolowczuk I & Lee A. (2000) Therapeutic immunisation against *Helicobacter pylori* infection in the absence of antibodies. *Immunology and Cell Biology* **78**: 28-30. (IF = 3.03).
- 15) **Sutton P**, Wilson J, Genta R, Pappo J, Torrey D, Savinainen A & Lee A. (1999) A genetic basis for atrophy: dominant non-responsiveness and *Helicobacter*-induced gastritis in F1 hybrid mice. *Gut* **45**: 335-340. (Selected for editorial by *Gut* and *Helicobacter*).
- 14) Kempf M-C, Cesbron-Delauw M-F, Deslee D, Groß U, Hermann T & **Sutton P**. (1999) Different manifestations of *Toxoplasma gondii* infection in F344 and LEW rats. *Medical Microbiology and Immunology* **187**: 137-142.
- 13) **Sutton P***, Supply P*, Coughlan SN, Bilo K, Saman E, Trees AJ, Cesbron M-F & Loch C. (1999) Immunogenicity of recombinant BCG producing the GRA1 antigen from *Toxoplasma gondii*. *Vaccine* **17**: 705-714. *Joint first authors
- 12) Sakagami T, Vella J, Dixon MF, O'Rourke J, Radcliff F, **Sutton P**, Shimoyama T, Beagley K & Lee A. (1997) The endotoxin of *Helicobacter pylori* is a modulator of host-dependent gastritis. *Infection and Immunity* **65**: 3310-3316.
- 11) Ferru I, Rollin C, Estaquier J, **Sutton P**, Delacore M, Tartar A, Gras-Masse H & Auriault C. (1996) Comparison of the immune response elicited by a free peptide and a lipopeptide construct. *Peptide Research* **9**: 136-43.
- 10) **Sutton P**, Waring P & Müllbacher A. (1996) Exacerbation of invasive aspergillosis by the immunosuppressive fungal metabolite, gliotoxin. *Immunology and Cell Biology* **74**: 318-322.
- 9) **Sutton P**, Beaver J & Waring P. (1996) Evidence that gliotoxin enhances lymphocyte activation and induces apoptosis by effects on cyclic AMP levels. *Biochemical Pharmacology* **50**: 2009-2014.
- 8) Waring P, Mamchak A, Sjaarda A & **Sutton P**. (1995) DNA synthesis precedes gliotoxin-induced apoptosis. *Cell Death and Differentiation* **2**: 201-210.
- 7) **Sutton P**, Moreland A, Hutchinson I & Müllbacher A. (1995) Investigation of the immunosuppressive agent, gliotoxin, in organ transplantation. *Transplantation* **60**: 900-902.
- 6) **Sutton P**, Waring P & Müllbacher A. (1994) Lack of correlation between proliferative and colony-forming assays and the true regenerative potential of transplanted bone marrow. *Transplant Immunology* **2**: 348-349.

- 5) **Sutton P**, Newcombe N, Waring P & Müllbacher A. (1994) The *in vivo* immunosuppressive activity of gliotoxin, a metabolite of human pathogenic fungi. *Infection and Immunity* **62**: 1192-1198.
- 4) Jiang H, Newcombe N, **Sutton P**, Lin Q, Müllbacher A & Waring P. (1993) Synthesis and activity of new epipolythiopiperazine-2,5-dione compounds. *Australian Journal of Chemistry* **46**: 1743-1754.
- 3) Sarawar S, Sparshott S, **Sutton P**, Yang C, Hutchinson I & Bell E. (1993) Rapid re-expression of CD45RC on rat CD4 T cells *in vitro* correlates with a change in function. *European Journal of Immunology* **23**: 103-107.
- 2) Hutchinson I, **Sutton P** & Stoddart R. (1992) Cell surface carbohydrates in the immune response. *Annals of the Rheumatic Diseases* **51**: 1273.
- 1) **Sutton P**, Stoddart R & Hutchinson I. (1992) Altered patterns of glycosylation associated with activation. *Immunology* **76**: 472-477.

Book Chapters

Lee A & **Sutton P**. (1998) *Helicobacter pylori* and long term survival in the gastric mucosa: Is immunomodulation the key? In: Old Herborn University Seminar Monographs. 11: 70-87. (Eds: Cebra, Heidt, Rusch, van der Waaij & Walker) Herborn Litterae.

Lee A, **Sutton P** & Doidge C. (1998) Towards vaccination: What progress? In: *Helicobacter pylori*: Basic mechanisms to clinical cure. 462-470. (Eds: Hunt & Tytgat) Kluwer Acad. Publ., Dordrecht.

Lee A & **Sutton P**. (1997) Immunisation against *Helicobacter pylori*: Challenges for the mucosal immunologist. In: Mucosal solutions, Advances in Mucosal Immunology. **2**: 99-109. (Eds: Husband, Beagley, Clancy, Collins, Cripps & Emery) University of Sydney.

Longdom Journals Press Releases. RECENT POSTS. Therapeutic dilemma in the repression of severe acute respiratory syndrome coronavirusâ2 proteome. Dec 17, 2020. Revisiting potential druggable targets against SARSâCoVâ2 and repurposing therapeutics under preclinical study and clinical trials. Journal Network manages over 325 peer-reviewed, open access publications. We supply our own managing editors while connecting well-qualified and vetted associate editors to publication submission to provide additional review services. All titles are indexed in UlrichsWeb and Google Scholar. You can browse the list of journals under our management, or search for specific titles. Peer review journals. The best way to verify a claim and instill it as universally accepted scientific knowledge is through a review. If someone devises a theory that they have found a reason for a natural phenomenon then they can submit a report to be reviewed by other experts in that domain. They can test it for its correctness. If the findings are found to be true then it is included in peer review journal. It usually contains a lot of knowledge about how they derived the hypothesis and how they tested it out and how the hypothesis turned out to be true. The journal began publication in 1963. Indian Pediatrics has a permanent Editorial Office situated at New Delhi, India. It is published monthly and has a current circulation of print/e-copies about 28,000. Publications in peer-reviewed journals. Selected journal publications by BIS economists, 2014-2020. Forthcoming. "Foreign banks and trade" (S Claessens and N van Horen), Journal of Financial Intermediation, forthcoming. "Exchange rates and prices: evidence from the 2015 Swiss franc appreciation" (R Auer, A Burstein, S Lein), American Economic Review. "Financial crisis, US unconventional monetary policy and international spillovers" (F Zhu, A Filardo, Q Chen and D He), Journal of International Money and Finance. 2020. "A loan-level analysis of financial resilience in Mexico" (C CantÃ, R Lobato, C LÃpez and F LÃpez-Gallo), Journal of Banking & Finance, September 2020. "Does informality facilitate inflation stability?"